NICE recommends weight loss drug semaglutide for obese adults

Press/Media: Expert comment

Description

BMJ news article

Period8 Feb 2022

Media coverage

1

Media coverage

  • TitleNICE recommends weight loss drug semaglutide for obese adults
    Degree of recognitionInternational
    Media name/outletBMJ
    Country/TerritoryUnited Kingdom
    Date8/02/22
    DescriptionCommenting on the guidance, Akheel Syed, a consultant endocrinologist at Salford Royal NHS Foundation Trust, welcomed the recommendation, noting that although a similar once-daily weight loss treatment (liraglutide) was already available, semaglutide had the “advantage of once weekly administration, which is much better for patients, and has superior efficacy.” He added that the recommendation of lower BMI thresholds for people from some ethnic minorities, “in recognition of their higher risk of morbidity from obesity, is particularly welcome.”

    However, Syed emphasised that “equitable access to
    novel and expensive medical treatments remains an
    issue up and down the country,” and he called for
    better funding to “ensure the best care for patients
    with obesity.”
    URLhttps://doi.org/10.1136/bmj.o340
    PersonsAkheel Syed